Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for Tumor Necrosis Factor-Alpha (TNF-) and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Adalimumab specifically binds to TNF alpha and blocks its interaction with p55 and p75 cell surface TNF receptors and reduces the inflammation and subsequently improves the patients health. Drug level quantification can be important to adapt patient prescription or to switch to an alternative TNF inhibitor drug. However the use of Adalimumab is associated with the development of anti Adalimumab antibodies. The consequences of an immune response range from transient appearance of antibody without any clinical significance to severe life-threatening condition. The DeQuantoTM anti Adalimumab (Humira) Immunogenicity ELISA kit can be efficiently used for monitoring the Anti Adalimumab antibodies The DeQuanto Anti Adalimumab (Humira) immunogenicity ELISA kit is an ELISA based immunoassay. The antibodies to Adalimumab present in the sample binds to pre coated Adalimumab on polystyrene microtiter plate. Non bound or the excess substances are removed by washing. Horseradish Peroxidase (HRP) labeled Adalimumab is added to the wells, which bind to the Anti Adalimumab antibody in the micro-wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the micro-wells. A color product is formed in proportion to the amount of Anti Adalimumab Antibody present in the sample. The color development is stopped by addition of a stop solution. The absorbance is measured at 450 nm in a microtiter plate reader.

ACCURACY AND PRECISION: Inter and intra assay precision %RE 20%

SELECTIVITY: Tested in Human Plasma Matrices MRD: 1/20

DILUTION LINEARITY: Tested and passes with %RE 20%

ASSAY TIME: 3-4 Hours